Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.
Paris (France), February 13, 2017 – 18:00 CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent (n° 15/232,844) relating to the Company’s candidate AsiDNA™, a first-in-class product that prevents tumor cells from repairing their DNA.
AsiDNA™ is composed of 64 nucleotides consisting of two strands of 32 nucleotides of complementary sequence, with a particular sequence and is already protected internationally, including in the United States.
This new patent protects any related compounds comprised of between 40 and 400 nucleotides in any sequence as well as related pharmaceutical composition and related methods for treating cancer. It provides Onxeo with a very broad scope of protection in this class of compounds.
The allowance of this patent, a few months after its filing in August 2016, confirms the innovative science behind the AsiDNA™ technology, that uses a “bait” to block the tumor DNA repair pathways.
This newly allowed patent will expire in mid-2031. This term could be further extended to 2036 through the patent term extension (PTE).
“Obtaining this new patent demonstrates that we are able to generate IP rights over broad claims. This is strategically important for Onxeo as it significantly reinforces our unique competitive position. AsiDNA™ is a breakthrough technology for the treatment of cancer and the expansion of the intellectual property related to AsiDNA™ is paramount to realizing its full potential and value to our shareholders.” commented Judith Greciet, CEO of Onxeo.